Socio-demographic, clinical and cognitive characteristics of the sample.

<p>Socio-demographic, clinical and cognitive characteristics of the sample.</p

Resting-state components.

<p>Resting-state components.</p

Clinical characteristics of parents.

<p>Clinical characteristics of parents.</p

Partial regression plot depicting correlation between VOI signal values and grey matter volume in the left caudate (SZ-offspring).

<p>Partial regression plot depicting correlation between VOI signal values and grey matter volume in the left caudate (SZ-offspring).</p

Effect size of CGAS on TAS (and 95% CIs).

<p>Effect size of CGAS on TAS (and 95% CIs).</p

Sociodemographic characteristics and total antioxidant status (TAS).

<p>Sociodemographic characteristics and total antioxidant status (TAS).</p

Coefficients of linear regression models between clinical assessment and TAS level at each visit point.

<p>Coefficients of linear regression models between clinical assessment and TAS level at each visit point.</p

Relationship between total antioxidant status (TAS) and Children's Global Assessment Scale (CGAS) scores over a two year follow-up.

<p>Relationship between total antioxidant status (TAS) and Children's Global Assessment Scale (CGAS) scores over a two year follow-up.</p

Relationship between CGAS score and TAS level at baseline and at two-year follow-up assessment.

<p>a) At baseline, there is a positive significant relationship between CGAS and TAS indicating that the better the patient's functioning, the higher his level of TAS; b) at one year and at two years of follow-up, this relationship is significantly reversed, with patients with the highest levels of TAS having the worst functionality.</p

jop-2017-3257-File005 – Supplemental material for Impact of <i>NTRK2, DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis

<p>Supplemental material, jop-2017-3257-File005 for Impact of <i>NTRK2, DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology</p